<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113020</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-233/CPH-003</org_study_id>
    <secondary_id>U1111-1152-9381</secondary_id>
    <nct_id>NCT02113020</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to examine the clinical pharmacology properties of
      TAK-233 in healthy female subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to examine the pharmacodynamics and the safety of
      TAK-233 administered as a single dose in healthy women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in motor threshold for urethral sphincter contraction.</measure>
    <time_frame>0.5 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in motor threshold for urethral sphincter contraction.</measure>
    <time_frame>3 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in motor threshold for urethral sphincter contraction.</measure>
    <time_frame>6 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Treatment emergent adverse events, vital signs, weight, safety ECG, and clinical laboratory tests (hematology, serum chemistry, and urinalysis).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Clinical Pharmacology</condition>
  <arm_group>
    <arm_group_label>TAK-233</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-233</intervention_name>
    <description>Oral administration of TAK-233</description>
    <arm_group_label>TAK-233</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral admininstration of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who understand the contents of this clinical trial and who the investigator
             or sub-investigator consider able to comply with the procedures of the clinical trial

          2. Subjects who can sign the informed consent form and can date the form without
             assistance before starting the procedures of the clinical trial

          3. Healthy Japanese women

          4. Subjects aged ≥ 20 and ≤ 40 years at the time of consent

          5. Subjects with body weight ≥ 45 kg and BMI ≥18.5 and ≤ 25.0 kg/m2 at the time of
             screening

          6. Women of child bearing potential who agree to take specified contraceptive measures
             regularly from the time of consent until 4 weeks after the end of the last assessment
             in the fourth treatment period

        Exclusion Criteria:

          1. Subjects who received TAK-233 within 16 weeks before the start of initial
             administration

          2. Subjects who have previously received TAK-233 during treatment or during participation
             in another clinical trial

          3. Employees of the medical institution conducting this clinical trial and their
             family/dependents (e.g., husband or wife, parents, children, and siblings), or
             subjects who may be coerced to agree to participate in the clinical trial

          4. Subjects with poorly controlled and clinically significant neurological,
             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal (including
             chronic costiveness), urological (including dysuria), autoimmune, endocrine, or
             psychiatric diseases or other abnormalities which may affect the subject's
             participation in the clinical trial or results of the clinical trial

          5. Subjects with hypersensitivity to TAK-233 related substances, or excipients of these
             products

          6. Subjects whose urine tested positive for drug abuse at screening

          7. Subjects with a history of drug abuse (defined as the use of illegal drugs) or alcohol
             dependence within 52 weeks before the screening assessments, or subjects who are not
             willing to stop alcohol intake or drug use during their participation in the clinical
             trial

          8. Subjects who need to take prohibited concomitant medications, vitamins, or foods
             listed in listed in what?

          9. Pregnant or lactating women, women expecting to be pregnant before giving consent,
             during this clinical trial, or within 4 weeks after the completion of this clinical
             trial, or women who are planning to donate their ova during this period

         10. Subjects with currently active cardiovascular diseases, central nervous system
             diseases, hepatic diseases, hematopoietic diseases, renal failure, metabolic
             disorders, endocrine disorders, serious allergies, asthma, hypoxemia, hypertension,
             convulsion, allergic exanthema, or urological disorders (subjects with peptic ulcer,
             convulsive disorders, or arrhythmia also fall this category)

         11. Subjects that have any of the following diseases/surgical interventions that may
             affect drug absorption: digestive system disorders (malabsorption, esophageal reflux,
             peptic ulcer, erosive oesophagitis, frequent heartburn (at least once a week), or
             surgical interventions (e.g., cholecystectomy), or subjects who have had prior history
             of any of these diseases/surgical interventions within the last 24 weeks

         12. Subjects with a history of cancer (excluding subjects whose basal cell carcinoma has
             been in remission for at least 5 years

         13. Subjects that have tested positive for hepatitis B surface antigen (HBsAg), hepatitis
             C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, or
             syphilis serological reaction at screening

         14. Subjects who took nicotine-containing products (e.g., cigarette, pipe tobacco, cigar,
             chewing tobacco, nicotine patch, and nicotine gum) within 28 days before
             hospitalization

         15. Subjects for whom blood collection from peripheral veins is difficult

         16. Subjects who donated at least 200 mL of whole blood within 4 weeks before the start of
             the initial administration, or subjects who donated at least 400 mL of whole blood
             within 16 weeks before the start of the initial administration

         17. Subjects who donated at least 400 mL (in total) of whole blood within 52 weeks before
             the start of the initial administration

         18. Subjects who donated blood components within 2 weeks before the start of the initial
             administration

         19. Subjects with clinically significant abnormalities on the electrocardiogram recorded
             at screening or hospitalization (Day -1 of the first treatment period)

         20. Subjects who had a QTcF interval of &gt; 470 msec or a PR interval of &lt; 120 msec or &gt; 220
             msec on the electrocardiogram recorded at screening or hospitalization

         21. Subjects with a systolic blood pressure of &lt; 100 mmHg or &gt; 140 mmHg and a diastolic
             blood pressure of &lt; 60 mmHg or &gt; 90 mmHg at screening or hospitalization

         22. Subjects with a heart rate of &lt; 50 bpm or &gt; 90 bpm at screening or hospitalization

        22. Subjects unlikely to comply with the protocol, or subjects the investigator or
        sub-investigator considers ineligible for participation in the clinical trial due to other
        reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

